^
Association details:
Biomarker:EGFR L858R
Cancer:Non Small Cell Lung Cancer
Drug:BI-4020 (EGFR inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Title:

EP08.02-085 In vitro Activity and Potential Resistance Mutations Against BI-4020, a 4th-generation EGFR-TKI

Published date:
07/12/2022
Excerpt:
We observed that BI-4020 was active against Ba/F3 cells with EGFR exon 19 deletion (Del19) or L858R mutation...only E709G and L718Q conferred high-level resistance to BI-4020 when L858R was present as a sensitizing mutation.